AllPennyStocks.com SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets

On a call on Monday, the company set a list price of $11,659 per vial of Isembyld, or about $310,000 a year for a typical patient.

Other Penny Stock Movers

This Critical Minerals Explorer Just Found Where to Look Next
Maiden Drill Campaign at Onuki Zone Concludes Under Sumitomo Earn-In
High-Grade 190 g/t Gold Grab Sample Highlights Manitoba Quartz Vein Expansion
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top